The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
Open accessAbstract
BACKGROUND: Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. METHODS: We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected incidence within 21 days after the first dose and 30 days after the second dose, independent of certainty of diagnosis; and by calculating the rate ratio 30 days after the second dose as compared with unvaccinated persons. RESULTS: Among 304 persons with symptoms of myocarditis, 21 had received an alternative diagnosis. Of the remaining 283 cases, 142 occurred after receipt of the BNT162b2 vaccine; of these cases, 136 diagnoses were definitive or probable. The clinical presentation was judged to be mild in 129 recipients (95%); one fulminant case was fatal. The overall risk difference between the first and second doses was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46). As compared with the expected incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6.40) and was highest after the second dose in male recipients between the ages of 16 and 19 years (13.60; 95% CI, 9.30 to 19.20). The rate ratio 30 days after the second vaccine dose in fully vaccinated recipients, as compared with unvaccinated persons, was 2.35 (95% CI, 1.10 to 5.02); the rate ratio was again highest in male recipients between the ages of 16 and 19 years (8.96; 95% CI, 4.50 to 17.83), with a ratio of 1 in 6637. CONCLUSIONS: The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the vaccine was associated with increased risk of myocarditis in Israeli participants, reaching a rate of approximately 3 events per 100,000 persons.398–400”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [399]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citationSafety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Mei, R., Raschi, E., Forcesi, E., Diemberger, I., Ponti, F. D., & Poluzzi, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.054 · Cited by 84
Surveillance Guidelines for Smallpox Vaccine (vaccinia) Adverse Reactions
Casey, C., Vellozzi, C. J., Mootrey, G. T., Chapman, L. E., McCauley, M. M., Roper, M. H., Damon, I. K., & Swerdlow, D. L. (2006) · PsycEXTRA Dataset · doi:10.1037/e506942006-001 · Cited by 58
Research works printed but not linked: 1
- Sahai H Khurshid A. Statistics in epidemiology: methods techniques and applications. Boca Raton FL: CRC Press 1996.
Cited by
Sorted by citations
Items 501–598 of 598
Gabrić, P. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/sjhra
Wi(e)der SARS-CoV-2: Epidemiologie, Booster und Impfstoffkombis
Welte, T. (2021) · Pneumo News · doi:10.1007/s15033-021-2785-x
Human vaccines & immunotherapeutics: news October 2021
(2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2003076
Ling, R. R., Ramanathan, K. R., Tan, F. L., Tai, B. C., Somani, J., Fisher, D. A., & MacLaren, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000665
(2022) · Reactions Weekly · doi:10.1007/s40278-022-08984-6
COVID‐19 Vaccine Efficacy and the Evidence on BoostersPreprint
Black, B. S., & Thaw, D. B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987991
KEJADIAN MIOKARDITIS PASCA PEMBERIAN VAKSIN COVID-19 BERBASIS mRNA
Indonesia, U. M., & Tambunan, R. T. H. (2021) · Majalah Ilmiah METHODA · doi:10.46880/methoda.vol11no3.pp176-184
2 Jahre COVID-19-Pandemie – was haben wir gelernt?
Maisch, B., & Dörr, R. (2022) · Herz · doi:10.1007/s00059-022-05097-8
Myokarditis nach COVID-19-Impfung: Daten der israelischen Impfkampagne
(2022) · Pädiatrie up2date · doi:10.1055/a-1734-5227
Incidence of Myocarditis after Messenger RNA Vaccine for COVID-19 in Young Male Recipients
Kato, S., Horita, N., & Utsunomiya, D. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.02.010
Covid-19 disease and SARS-COV-2 vaccines: the balance between risks and benefits
Nadejda, S., Angela, B., Durnea, A., Caraus, A., & Moscalu, V. V. (2022) · Bulletin of the Academy of Sciences of Moldova Medical Sciences · doi:10.52692/1857-0011.2022.1-72.17
Lai, D., Lu, J., Lim, D. A., Wang, H., & Zhang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1741089/v1
Placing the risk of myopericarditis following COVID-19 vaccination into perspective
Liuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac296
Myocardial injury after COVID-19 infection and vaccination. Two sides of the same coin or different?
Ochs, M. M., & Korosoglou, G. (2022) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-022-02651-7
Screening per rilevare il maltrattamento in un ambiente ospedaliero pediatrico
Valletta, E. A. (2022) · QUADERNI ACP · doi:10.53141/peqacp.2022.2.am1
Myopericarditis and COVID-19 Vaccination
Rao, M. (2022) · Journal of Virology and Viral Diseases · doi:10.54289/jvvd2200110
COVID-19 Vaccines and Myopericarditis: A Nuanced Story
Jacobs, M., & Kalogeropoulos, A. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081242
Rohman, M. S., Fajar, J. K., Soegiarto, G., Wulandari, L., Anshory, M., Ilmawan, M., Marlysawati, D., Purnamasari, Y., Kusuma, A. P., Asmiragani, A., et al. (2022) · F1000Research · doi:10.12688/f1000research.122139.1
SARS-COV-2 and Other mRNA Vaccines
Jackson, N. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_6
Fevery, J., & Dallmeier, K. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.111
Myokarditis und Perikarditis nach COVID-19-mRNA-Impfung
Augustin, M., Hallek, M. J., & Nitschmann, S. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01421-w
Porcari, A. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001395
Fulminant Myocarditis in a 76-Year-Old Lady after Spikevax Vaccination: A Case Report.
Cheong, K.-I., Hsin, H., How, C., Wu, Y., Chiu, K., & Huang, J.-H. (2022) · PubMed Central · doi:10.6515/acs.202211_38(6).20220508a
Amelioration of myocarditis after COVID-19 vaccination by low-dose boosterPreprint
Miyazaki, K., Fujii, T., Mori, K., Tamimoto, R., Nagamatsu, H., Murakam, T., Cho, Y., Goto, S., & Mori, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2117240/v1
An Investigation into the Association of COVID-19 and Viral Myocarditis: A Literature Review
Hasan, Z., Rahimpoor-Marnani, P., Kannan, V., Misra, S., & Mardon, A. A. (2022) · Canadian Journal of Medicine · doi:10.33844/cjm.2022.6021
Miocarditis aguda en varón joven tras la primera dosis de la vacunación frente al SARS-CoV-2
Blanquer, L. G., Sanjuán, P. H., Gómez-Cerezo, J. F., & González‐Ruano, P. (2022) · Revista Española de Casos Clínicos en Medicina Interna · doi:10.32818/reccmi.a7n3a13
Adverse cardiac events following mRNA COVID-19 vaccination: A systematic review and meta-analysis
Putri, E. A. C., Munir, M., Setiawan, H. K., Herawati, L., Sari, G. M., Wungu, C. D. K., Susilo, H., & Sutanto, H. (2022) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres22.1524_11.1.76
Systemic lupus erythematosus myocarditis after COVID-19 vaccination
Sogbe, M., Matteo, A. B.-D., Frisco, I. M. D., Bastidas, J. F., Salterain-González, N., & Gavira, J. J. (2023) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2022.06.006
COVID-19 vaccine-associated myocarditis (Russian translation)
Morgan, M. C., Atri, L., Harrell, S., AlJaroudi, W., & Berman, A. E. (2022) · Juvenis scientia · doi:10.32415/jscientia_2022_8_6_41-55
5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era"
Mukae, H. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.578
Mathew, D., Agarwal, S., Sherif, A. A., & Bumrah, K. (2023) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.1387
Acute cardiac events after COVID-19 vaccines and during spontaneous SARS-CoV-2 infection
Marabotti, C., & Pingitore, A. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001464
University-age vaccine mandates: reply to Lam and Nichols
Høeg, T. B., Krug, A., Baral, S., Jamrozik, E., Keshavjee, S. A., Lemmens, T., Prasad, V. K., Makary, M. A., & Bardosh, K. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2023-109163
Central diabetes insipidus following COVID-19 mRNA vaccination: a case report
Kim, M., Hahm, J. R., Jung, J., Jung, J. H., Kim, K. Y., Kim, H., Baek, J. H., Shin, H. S., Kang, K. R., & Kim, S. K. (2023) · Kosin Medical Journal · doi:10.7180/kmj.23.105
Perlman, S. M., & Denison, M. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00017-7 · Cited by 2
Myocarditis after vaccination for COVID-19
Hamatani, Y., & Akao, M. (2023) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.34.452
COVID-19 Vaccine–Associated Myocarditis Considerations for Competitive Athletes
Tso, J., & Kim, J. H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01009-z
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
(2021) · Reactions Weekly · doi:10.1007/s40278-021-03978-1
Keinan‐Boker, L., Fluss, R., Dichtiar, R., Rosenberg, A., Lassan, M. B., & Huppert, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3465256/v1
Self-citationAlami, A. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15810
Gomes, M. M. N., Melo, B. C., Costa, D. M., Medina, M. S. L., Silva, M. J. G., & Neto, M. B. D. C. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-508
Análise da miocardite como desfecho da vacinação para COVID-19
Santos, D. M., Marotta, C. D. S., & Lima, R. F. D. S. (2024) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e14543.2024
Arbel, Y., Arbel, Y., Kerner, A., & Kerner, M. (2024) · Cogent Social Sciences · doi:10.1080/23311886.2023.2299136
悠, 松., 喬之, 鈴., 拓磨, 中., 明日美, 水., 雄太, 小., 琢真, 佐., & 峰司, 早. (2024) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12883
Shoaibi, A., Matuska, K., Lloyd, P. C., Wong, H., Gruber, J. F., Clarke, T. C., Cho, S., Lassman, E., Lyu, H., McEvoy, R., et al. (2024) · medRxiv · doi:10.1101/2024.02.20.24303089
Lai, D., Lim, D. A., Lu, J., Wang, H., Huang, T., & Zhang, Y. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12595
The Most Effective Drugs in the Treatment of Myocarditis Disease
o’g’li, S. S. N., & Makhmudovich, A. H. (2024) · Health & Medical Sciences · doi:10.47134/phms.v1i2.214
Myocardial Injury After COVID-19 Vaccine-Associated Myocarditis: Natural History
Alhussein, M. M. (2022) · Annals of Radiology · doi:10.52338/aor.2022.3020
Blagova, O. V., Харисовна, А. Д., Savina, P. O., Lutokhina, Y. A., Pavlenko, E. V., Novikova, I. V., Zaitsev, A., & Коган, Е. А. (2024) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio202417021184
Cacciatore, C., Baudet, M., Jean, E., Presente, S., Para, M., Sonneville, R., Arangalage, D., Abdallah, N. A., de Fontbrune, F. S., Prata, P. H., et al. (2024) · Current Research in Translational Medicine · doi:10.1016/j.retram.2024.103449
She, C.-H., Tsang, H.-W., Yang, X.-T., Tsao, S., Tang, C. S., Chan, S. H. S., Kwan, M. Y., Chua, G. T., Yang, W., & Ip, P. (2024) · BMC Genomic Data · doi:10.1186/s12863-024-01238-6
Kim, J. A., Won, H., Lim, E., & Choi, N. (2024) · Journal of Health Informatics and Statistics · doi:10.21032/jhis.2024.49.2.160
Cardiac effects of drugs and vaccines used to treat and prevent COVID-19
Cubeddu, L. X., & Tailor, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00048-2
COVID-19 vaccines and their impact: An overview
Khong, K.-W., & Hung, I. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00002-0
Deciphering the Cardiovascular Conundrum of COVID-19: An In-depth Review
Yadav, S. K., & Chand, S. (2024) · Coronaviruses · doi:10.2174/0126667975299242240607103902
Zahrani, E. A., Elsafi, S. H., Alkharraz, R., Sahal, N., Almansori, M., Alhababi, A., & Alkharraz, Z. S. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s467586
Koller, Á., Pelle, J., Béres, B., & Takács, J. (2024) · Sprint, sports research international · doi:10.1556/1020.2023.10001
Siripanthong, B., & Chahal, C. A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00003-0
Löfström, E., Eringfält, A., Kötz, A., Tham, J., & Undén, J. (2024) · Apmis · doi:10.1111/apm.13489
Pakanen, L., Nieminen, T. A., Kuvaja, P., Nohynek, H., Goebeler, S., Artama, M., & Hovi, P. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100645
Chlubek, M., & Baranowska‐Bosiacka, I. (2022) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.830
A Comprehensive Study of Vaccine Safety Monitoring System: Challenges an Solution
Wasiullah, M., Yadav, P., Vishwakarma, M. M. V. M. M., & Fatima, A. F. A. (2025) · International Journal of Pharmaceutical Research and Applications · doi:10.35629/4494-100224332442
Tu, P. H. T., Bazelier, M. T., Klungel, O. H., & Bots, S. H. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128722 · Cited by 1
(Constrictive pericarditis after SARS-CoV-2 vaccination: a case report and literature review)
Simovicova, V., Danková, M., Drangová, E., Hulman, M., & Gonçalvesová, E. (2025) · Cor et Vasa · doi:10.33678/cor.2024.107
Yusuf, O., Omotosho, A. O., Moore, S., & Khan, A. (2025) · Cureus · doi:10.7759/cureus.88611
Global burden of myocarditis in adolescents and young adults, 1990–2019
Zhang, M., Li, F., Bai, J., Jiang, Z., Zhu, Z., Qi, X., Niu, L., Wu, Y., Tang, X., Zhao, H., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05159-9
Efficacy and Safety of Influenza and COVID-19 Vaccines
Kawai, N., Ikematsu, H., & Bando, T. (2025) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.r25001
COVID-19 vaccination: effectiveness, uncertainties, and safety considerations (2020–2025)
Merante, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2585063
Increased cardiomyopathy risk after viral infection evidence from a nationwide cohort in Taiwan
Yu, P.-C., Hsin, H., Chung, R., Huang, S.-H., Weng, T., Wang, B., Chung, C., Huang, Y.-C., Chien, W., Lin, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-25454-x
Methi, F., Gran, J. M., Valberg, M., Kinge, J. M., Telle, K. E., & Magnusson, K. (2024) · Figshare · doi:10.6084/m9.figshare.26585244
She, C. H., Tsang, H. W., Yang, X., Tsao, S. S., Tang, C. S.-M., Chan, S. H., Kwan, M. Y. W., Chua, G. T., Yang, W., & Ip, P. (2024) · Figshare · doi:10.6084/m9.figshare.25989335
She, C. H., Tsang, H. W., Yang, X., Tsao, S. S., Tang, C. S.-M., Chan, S. H., Kwan, M. Y. W., Chua, G. T., Yang, W., & Ip, P. (2024) · Figshare · doi:10.6084/m9.figshare.26730463
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Leoni, O., Vignati, E., Pavesi, G., & Gori, A. (2022) · Figshare · doi:10.6084/m9.figshare.21547340
Boker, L. K., Fluss, R., Dichtiar, R., Rosenberg, A., Lassan, M. B., & Huppert, A. (2024) · Figshare · doi:10.6084/m9.figshare.26711282
Self-citationShe, C. H., Tsang, H. W., Yang, X., Tsao, S. S., Tang, C. S.-M., Chan, S. H., Kwan, M. Y. W., Chua, G. T., Yang, W., & Ip, P. (2024) · Figshare · doi:10.6084/m9.figshare.26730466
She, C. H., Tsang, H. W., Yang, X., Tsao, S. S., Tang, C. S.-M., Chan, S. H., Kwan, M. Y. W., Chua, G. T., Yang, W., & Ip, P. (2024) · Figshare · doi:10.6084/m9.figshare.25989251
Liang, H., Khairunnasa, F., & Yuan, H. (2026) · Vaccine X · doi:10.1016/j.jvacx.2025.100774
Sannathimmappa, M. B., Nambiar, V., & Satti, S. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03269
McEvoy, R., Hervol, J. R., Zhang, Y., Wagner, E. M., Lindaas, A., Jiao, Y., Xu, S., Weintraub, E., Qian, L., Hong, V. X., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128460
Inflammation and Heart Failure
Kim, K., Kim, D., & Eisen, H. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-12629-0_20
Evidence for Autoimmunity in the Pathogenesis of COVID-19-Induced Myocarditis
Tuvali, O., Welt, M., Benaim, C., Fassler, M., & George, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062694
COVID-19 Vaccination Strategy and Evidence in Korea
Hwang, Y. H., & Park, W. B. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e114
Mitsakos, K., Heuer, P. E., Beninati, T., Polley, D., Schloeffel, R. J., & Hudson, B. J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1784007
Bastać, D., Joksimović, Z., Bastać, M., & Nešović, P. (2026) · Timocki medicinski glasnik · doi:10.5937/tmg2601038b
Influence of COVID-19 Pandemic on Early-Onset Myocardial Infarction in Adults
Gouniyal, T., Chaudhary, S., & Kumar, P. (2026) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.5.2.19
Choi, K., Choi, S., Joe, D., Seo, Y., Ham, J., Chung, H., Ramadan, Y., & Park, Y. S. (2026) · Mediators of Inflammation · doi:10.1155/mi/8991922
The experimentality of real-world evidence studies: Turning a population into value
Pinel, C., & Raz, A. (2026) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2026.100812
Tamagnini, E., Simonelli, L., Palus, M., Rezzonico-Jost, T., Lazzarini, E., Mangani, D., Hönig, V., Dvořáková, M., Arbon, D., Gambini, F., et al. (2026) · Vaccines · doi:10.3390/vaccines14070568
Guo, S., Cao, C., Qin, S., Shang, L., Qiao, X., Su, D., & Pang, Y. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.06.011
Rochitte, C. E., & Carneiro, A. C. D. C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-12497-6.00030-0
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830
Brosh-Nissimov, T., Rahav, G., Stienlauf, S., & Moses, A. E. (2026) · Research Square · doi:10.21203/rs.3.rs-11025948/v1
DESENVOLVIMENTO DE VACINAS PARA COVID-19: UMA REVISÃO COM ÊNFASE NAS REAÇÕES ADVERSAS
Garrido, R. G., & Miler-da-Silva, L. L. (2026) · Colloquium Vitae · doi:10.5747/cv.2026.v18.v394
Metadata
- Authors
- Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M. S., Keinan-Boker, L., & Alroy-Preis, S.
- Affiliations
- Bar-Ilan University (IL)
- From the Department of Internal Medicine B, Division of Immunology–Rheumatology, and Wohl Institute for Translational Medicine (D.M.) and the Departments of Cardiology (R.A., O.A.), Pathology (K. Meir), and Radiology (D.C.), Hadassah Medical Center, Braun School of Public Health (E.A.), Jesselson Integrated Heart Center, Shaare Zedek Medical Center (T.H., N.L.), and the Department of Family Medicine (I.M.), Faculty of Medicine, Hebrew University of Jerusalem, the Divisions of Epidemiology (E.A., N.C., E.J.H., E.N.), Patient Safety (S.O.-C., D.A.), and Medicine (I.L.), Israeli Ministry of Health (M.B., R. Dichtiar, D.N., Y.H., Y.L., L.K.-B., S.A.-P.), and Clalit Health Services (E.N., I.M.), Jerusalem, Israel Center for Disease Control, and Azrieli Faculty of Medicine, Bar-Ilan University (O.A.), Ramat Gan, the Department of Epidemiology and Preventive Medicine, School of Public Health (M.B., K. Muhsen), and Tel Aviv Sourasky Medical Center (R.B.-A.), Tel Aviv University, Tel Aviv, Ben Gurion University of ...
- Corresponding author
- Alroy-Preis, Sharon
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-02
- Volume
- 385
- Issue
- 23
- Pages
- 2140-2149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8531987
- OpenAlex
- W3204791524
- Cited by
- 599
- References
- 7
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 84 · 2023: 125 · 2022: 280 · 2021: 41
- FWCI
- 88.83
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- myocarditis, BNT162b2 mRNA vaccine, COVID-19 vaccination, vaccine adverse events, incidence, standardized incidence ratio, risk difference, second vaccine dose, young men, Israel, active surveillance, adverse event reporting, vaccine safety surveillance, COVID-19 mortality, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- COVID-19, BNT162 Vaccine, Adolescent, Adult, Echocardiography, Female, Hospitalization, Humans, Israel, Male, Middle Aged, Myocarditis, Retrospective Studies, Comorbidity, Incidence, Age Distribution, Sex Distribution, Kaplan-Meier Estimate, Young Adult, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review